Equine Recurrent Uveitis (ERU)
The Influence of Multiple Genetic Risk Factors for Chronic Uveitis in Appaloosas
Equine recurrent uveitis (ERU) is the leading cause of equine blindness, resulting from chronic and painful episodes of inflammation in the uveal tract of the eye. A definitive inciting cause for uveitis has not yet been determined; however, the inflammation is widely thought to be due to an immune-mediated reaction in genetically susceptible animals. Inflammation has been detected in the clinically normal eyes of chronically affected horses, suggesting that intraocular tissues are being destroyed even without overt signs of disease. Although uveitis occurs in all horse breeds, Appaloosa horses are eight times more likely to develop uveitis, frequently have a persistent form of the disease, and are nearly four times more likely to develop blindness than other breeds.
There is no cure for chronic uveitis in Appaloosa horses. Horses diagnosed with this disease are typically managed with topical anti-inflammatory drugs during acute flare-ups of disease. Recent work has demonstrated that placing a surgical implant containing the immunosuppressive drug cyclosporine directly into affected eyes can drastically improve disease in horses affected by uveitis and decrease the likelihood of developing blindness. If horses at high risk for developing uveitis could be identified prior to the onset of clinical disease, they could be monitored with frequent ophthalmologic examinations, and aggressive sight-sparing treatment options, such as cyclosporine implants, could be initiated at the first sign of inflammation.
We are evaluating two regions of the horse genome for functional genetic variants associated with chronic uveitis in Appaloosas. The goal of our research is to identify the functional genetic factors responsible for uveitis susceptibility in Appaloosa horses and to develop a genetic risk model for this disease. The genetic risk model will facilitate the generation of a genetic test so that individuals at high risk of developing uveitis can be identified and treatment initiated before the devastating clinical disease occurs. In addition to developing a genetic test, the information gained from this work will lead to an improved understanding of the biology of uveitis and better treatment options.
A.E.Dwyer, B.C.Gilger. Equine recurrent uveitis. In: Equine ophthalmology. (ed. B.C.Gilger). W.B.Saunders Co:
Philadelphia, 2005; 42-62.
Gilger BC, Malok E, Cutter KV, Stewart T, Horohov DW, Allen JB. Characterization of T-lymphocytes in the anterior
uvea of eyes with chronic equine recurrent uveitis. Vet Immunol Immunopathol 1999 October 1;71(1):17-28.
Dwyer AE, Crockett RS, Kalsow CM. Association of leptospiral seroreactivity and breed with uveitis and blindness in
horses: 372 cases (1986-1993). J Am Vet Med Assoc 1995 November 15;207(10):1327-1331.
Deeg CA, Thurau SR, Gerhards H, Ehrenhofer M, Wildner G, Kaspers B. Uveitis in horses induced by
interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. Eur J Immunol 2002 September;32(9):2598-2606.
Gilger BC, Wilkie DA, Clode AB, McMullen RJ, Jr., Utter ME, Komaromy AM et al. Long-term outcome after
implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet Ophthalmol 2010 September;13(5):294-300.
Sources of Research Funding
Morris Animal Foundation
Bernice Barbour Foundation
US Equestrian Foundation
University of Minnesota Equine Center and College of Veterinary Medicine
Minnesota Racing Commission
Minnesota Agricultural Experiment Station